Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Shenghuo Completes Phase II Trial of Ulcer Drug

publication date: Jul 18, 2007
Results Published Soon -- China Shenghuo (AMEX: KUN) has completed a Phase II trial in China of its Wei DingKang Soft Capsules, a product that is being tested for SFDA approval as a treatment for peptic ulcers. Results are expected in a few weeks. Like China Shenghuo's other products, the Wei DingKang Soft Capsules are based on Sanchi, which are derived from Panax notoginseng root. Although China Shenghuo is listen on an American exchange, its revenues come almost entirely from sales within China. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here